Skip to content

CONTRIBUTORS

Stephen Dover, CFA

Chief Market Strategist
Head of Franklin Templeton Institute

Originally published in Stephen Dover’s LinkedIn Newsletter, Global Market Perspectives. Follow Stephen Dover on LinkedIn where he posts his thoughts and comments as well as his Global Market Perspectives newsletter.

Hantavirus is in the headlines not because it’s widespread, but because a rare and severe cruise-ship outbreak involving the Andes virus variant created a dramatic story and concern that it could spread more broadly. Sadly, the hantavirus episode arrives with memories still fresh from widespread loss of life and severe economic fallout caused by the COVID-19 pandemic.

This week, I sat down with our health care and biotech analysts from Putnam Investments and Franklin Equity to get a fuller view of the hantavirus outbreak and what the implications could be for investors. We discussed its relevance for health care stocks, but also why this outbreak appears materially different from the early stages of COVID-19.

In what follows, I summarize the views expressed by Steve Burlingame, Akiva Felt and Alex Morse from Franklin Equity and by Mike Maguire and Noelle Tune from Putnam.

  • Serious, yes. Systemic, probably not. The outbreak has captured attention because contracting hantavirus can be fatal, but the evidence thus far points to a contained impact from human-to-human transmission.
  • This is a case where transmission matters more than headlines. For investors, the key question, therefore, is whether evidence subsequently emerges of a more widespread and sustained spread of hantavirus beyond close-contact settings.
  • Any near-term reaction in biotech may reflect optionality more than earnings power. Vaccine-platform names may attract attention in the media, but the commercial case will likely remain uncertain unless the outbreak becomes a significantly greater and more persistent public-health challenge.
  • The comparison with COVID-19 is understandable, but incomplete. Hantavirus can be more severe for infected individuals, yet it remains far less transmissible, which materially changes its public health ramifications.
  • mRNA promise does not ensure payoff. Development of vaccines or effective treatments is costly, and as a consequence the potential returns to biotechnology or pharmaceutical companies may be limited if the outbreak remains contained.
     

The message is simple: Watch infection transmission rates, not headlines. The key question in the next seven to 10 days is whether this virus remains contained or begins to spread into other populations, with broader public health and market implications.

For investors, our takeaway is that biotechnology remains an innovation-driven space where long-term returns depend less on headlines and more on disciplined assessment of clinical, regulatory and commercial viability.

WHAT ARE THE RISKS?

All investments involve risks, including possible loss of principal.

Equity securities are subject to price fluctuation and possible loss of principal. 

Investment strategies which incorporate the identification of thematic investment opportunities, and their performance, may be negatively impacted if the investment manager does not correctly identify such opportunities or if the theme develops in an unexpected manner. Focusing investments in the health care and biotechnology sectors carries much greater risks of adverse developments and price movements in such industries than a strategy that invests in a wider variety of industries.

WF: 10398459

Copyright ©2025. Franklin Templeton. All rights reserved.

This document is intended to be of general interest only. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund. The information provided for any individual security mentioned is not a sufficient basis upon which to make an investment decision. Investments involves risks. Value of investments may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD (“other foreign currency”). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in derivative instruments, this entails specific risks that may increase the risk profile of the investment product. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any share class with “(Hedged)” in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

Please contact your financial advisor if you are in doubt of any information contained herein.

For UCITS funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

For AIFMD funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the AIFMD Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 32a of the AIFMD Directive.

For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund(s)/ sub-fund(s) and will not be investing directly in the underlying assets of the fund(s)/ sub-fund(s).

This document is issued by Franklin Templeton Investments (Asia) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

Unless stated otherwise, all information is as of the date stated above. Source: Franklin Templeton.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.